你可能會喜歡
Blessed to have an incredible clinic, lab team, and collaborators. This holiday season, we came together to paint our shared vision for the future: a colorful, beautiful, and healthy brain—free of metastasis. Grateful for this talented, passionate, and committed team making this…
Kidney Cancer Highlights from ESMO 2025! @IKCCorg @myESMO #ESMO25 @OncoAlert @ONCOassist ikcc.org/summary-of-kid…
🚨 Breaking RCC update from Merck (Oct 28, 2025) Two back-to-back positive Phase 3 trials for belzutifan (WELIREG®) 👇 1️⃣ LITESPARK-022 – Adjuvant setting 📍 Pembrolizumab + Belzutifan vs Pembrolizumab alone ✅ Significant DFS improvement in resected clear-cell RCC after…
Thank you to @OSUCCC_James brilient Urooncologist Dr. @eric_facs for arrenging this outstanding @KidneyCancer local meeting and let us to spend time with @Brutus_Buckeye as well and sharing our expertise. @ChristianRolfo @HasanovLab @KimrynRathmell @OSU_Urology @OhioStateMedOnc
Outstanding talk at @KidneyCancer local community talk from our @OSUCCC_James and @OhioStatePIIO raising star Dr. @HasanovLab (Elshad Hasanov) 🙏🎉👏 pelotonia.org/peloton/a0sQj0… @OhioStateMedOnc @OSU_Urology #KCA #KidneyCancer #OSUCCC #Oncology #Research #Collaboration #GUOnc
🕺🏻🥳🎉 !!WOW!! Brutus seriously knows how to jazz up a crowd! Thanks for bringing your energy to our #kidneycancer patient education event today! #GoBucks @OSUCCC_James @Brutus_Buckeye
Empowering You @KidneyCancer Patient Education Event: Inspiring and comprehensive morning session and panel discussion by @GEVaughan1 @eric_facs @fuatbcr @lingbin_meng @MartyMakary @shawndason @OSUWexMed @OSU_Urology Tremendous progress in the field, yet many important questions…
Excited to join our @KidneyCancer for the upcoming local #KidneyCancer meeting! Connecting clinicians, patients, and researchers to advance #RCC care and #PrecisionOncology 💪 @OhioStateCancer @OSU_Urology @OhioStateMedOnc @HasanovLab
🚨 Registration closes soon! kidneycancer.org/event/empoweri… Join the KCA and @OhioStateMedOnc next week — October 25 for a FREE #kidneycancer edu event. Hear directly from experts and connect with others who understand. Special thanks to @eric_facs @KimrynRathmell 🧡
Wonderful dinner with @eric_facs and our team! Great discussions and excitement for tomorrow’s patient event at @OSUCCC_James! kidneycancer.org/event/empoweri…
So excited to welcome everyone today to @OSUCCC_James for a patient education symposium! We have an exciting group of speakers to lead our discussions on treatment, disease management, patient experiences, and so much more. Thank you @OhioState for your partnership!
The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel
📢 #ESMO25 concomitant paper: results from the LenCabo phase II trial of lenvatinib + everolimus vs cabozantinib post PD-1 ICI in #mccRCC @OncHahn annalsofoncology.org/article/S0923-…
@ScottHaake @VUMCDiscoveries showing impressive objective responses for angiogenically selected patients w #kidneycancer on #OPTICRCC - had patients on this #DOD funded trial @utswcancer #ESMO25 #ESMOAmbassadors @OncoAlert @myESMO
Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews #ESMO25 #ESMOAmbassadors @OncoAlert
Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert
Up-lifting post-PD1 head-to-head by @OncHahn in a Ph.II trial! Len/Eve vs Cabo in metastatic ccRCC with PD-1 1L progression. PFS HR 0.51 (95% CI 0.29-0.89); p= 0.02. ORR 53% vs 39% (ctrl) p=0.17. #ESMO25 #RCC @myESMO @OncLive @OncoAlert @Annals_Oncology
Impressive and remarkable biomarker-driven 1L by @DrScottHaake in OPTIC RCC, Ph.II trial: RNAseq-guided nivolumab+cabozantinib for angiogenic cluster 1/2. ORR 71% (PR 71%, SD 29%, PD 0); 100% tumor shrinkage (n=21). Prospectively selected tissue-based rna biomarker to guide…
🎯 adapting 1L treatment to mRNA Clusters in mRCC preliminary report of Angio Cluster 1-2 with Nivo-Cabo Excellent exploratory molecular-driven study!! 76% ORR without PD! @myESMO @OncoAlert @OncBrothers @urotoday @DrChoueiri @tompowles1 #ESMO25
PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the…
United States 趨勢
- 1. $BNKK N/A
- 2. Pond 195K posts
- 3. Good Monday 37.5K posts
- 4. #MondayMotivation 36.2K posts
- 5. Happy 250th 4,078 posts
- 6. Semper Fi 4,935 posts
- 7. Obamacare 217K posts
- 8. Rudy Giuliani 23.8K posts
- 9. Go Birds 3,148 posts
- 10. #Talus_Labs N/A
- 11. #SoloLaUniónNosHaráLibres N/A
- 12. Victory Monday 1,438 posts
- 13. #MondayVibes 2,589 posts
- 14. #LingHerHynessTiktokLive 494K posts
- 15. LINGLING BA HERHYNESS 494K posts
- 16. The BBC 474K posts
- 17. Edmund Fitzgerald 4,340 posts
- 18. Mark Meadows 21.6K posts
- 19. Devil Dogs 1,459 posts
- 20. Tina Peters 9,586 posts
你可能會喜歡
-
Dimitra R. Bakaloudi MD, MS, MPA
@DRBakaloudiMD -
Albert Jang, MD
@AJangMD -
Blessie Elizabeth Nelson MBBS, DMRT
@BlessieNelson -
Pedro C Barata, MD MSc FACP
@PBarataMD -
Pavlos Msaouel
@PavlosMsaouel -
Omar Alhalabi, MD
@OAlhalabiMD -
Andy Hahn
@OncHahn -
Sangeeta Goswami, MD,PhD
@SGoswamiMDPhD -
Kelsey Pan, MD, MPH
@KelseyPanMD -
Jinesh Gheeya, MD, PhD
@JineshGheeya -
Tarek Haykal, MD, MHS
@TarekHaykal1 -
Michael Serzan, MD
@MikeSerzanMD -
Canan Dirican
@CananDirican -
Hind Rafei
@HindRafei -
Elise Nassif Haddad
@NassifElise
Something went wrong.
Something went wrong.